Last updated: September 27, 2026
Aloxi, the branded formulation of palonosetron hydrochloride, is a mature antiemetic used to prevent chemotherapy-induced nausea and vomiting. Its commercial position was built on long duration of action, once-per-cycle intravenous dosing, and strong use in moderately and highly emetogenic chemotherapy protocols. The product’s core U.S. regulatory exclusivity has expired, generic palonosetron is available, and current value depends on institutional contracting, formulation preference, supply reliability, and combination products rather than patent-based pricing power.
Standalone global revenue is not consistently disclosed by current rights holders. Public filings generally report Aloxi within broader portfolios or regional product categories. The financial trajectory is therefore best assessed through regulatory milestones, generic entry, competitive displacement, and the economics of branded antiemetic procurement.
What is Aloxi and how does palonosetron compete in antiemetic therapy?
Aloxi contains palonosetron, a selective 5-HT3 receptor antagonist. It is approved for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy and acute nausea and vomiting associated with highly emetogenic chemotherapy in adults. An oral capsule formulation was also approved in the United States.
Palonosetron has a longer elimination half-life than older 5-HT3 antagonists:
| Product |
Active ingredient |
Approximate half-life |
Main commercial positioning |
| Aloxi |
Palonosetron |
About 40 hours |
Long-acting IV and oral 5-HT3 antagonist |
| Zofran |
Ondansetron |
About 3 to 6 hours |
Established generic short-acting alternative |
| Kytril |
Granisetron |
About 9 hours |
Generic 5-HT3 competitor |
| Akynzeo |
Netupitant/palonosetron |
Palonosetron component plus NK1 antagonist |
Fixed-dose prevention of acute and delayed CINV |
| Emend |
Aprepitant/fosaprepitant |
NK1 antagonist |
Combination or sequential antiemetic therapy |
Aloxi’s principal clinical differentiation is its duration of receptor coverage. The product has been used as part of guideline-based antiemetic regimens, frequently with dexamethasone and, for highly emetogenic chemotherapy, an NK1 antagonist. Those clinical advantages support utilization but do not prevent substitution once generic palonosetron is available.
When did Aloxi lose exclusivity and when did generic palonosetron enter?
The original U.S. product received FDA approval in July 2003. Its five-year new chemical entity exclusivity period therefore ended in 2008, subject to any applicable pediatric extension or formulation-specific exclusivity. The core product has been commercially exposed to abbreviated new drug application competition for many years.
Key milestones include:
| Event |
Date or period |
Commercial effect |
| U.S. approval of Aloxi injection |
July 2003 |
Established the original U.S. product |
| Five-year NCE exclusivity |
Ended in 2008 |
Opened the principal regulatory pathway for ANDA competition |
| Oral palonosetron approval |
2008 |
Expanded the dosage-form franchise |
| Generic palonosetron approvals and launches |
Primarily late 2010s onward |
Reduced price and contracting power for injection |
| Current market phase |
Mature generic market |
Volume remains, but branded premium is limited |
Generic injectable palonosetron products have been approved by multiple manufacturers, including major generic suppliers. The exact competitive roster varies by dosage strength, presentation, and current commercial availability. FDA approval of an ANDA does not itself establish commercial launch, but the presence of multiple approved generic products creates a low-barrier substitution environment for hospitals and oncology providers.
What patents protect Aloxi and what is the Orange Book status?
Aloxi’s principal U.S. commercial protection was based on patents covering palonosetron, its salts, pharmaceutical compositions, and use in preventing chemotherapy-induced nausea and vomiting. The relevant estate is now historical from a market-exclusivity perspective because the principal patent terms expired before the current generic market matured.
The Orange Book remains the controlling source for current listed patents and regulatory exclusivity. Aloxi is listed under the FDA’s Drugs@FDA database as NDA 021372. Orange Book records should be evaluated by dosage form because patents and exclusivity entries can differ between injection and oral products.[1][2]
The commercial conclusions are clear:
- The original palonosetron product is no longer protected by active core exclusivity that blocks generic entry.
- Formulation or method-of-use claims, where present, do not recreate the original broad product monopoly.
- A generic manufacturer can compete through an ANDA if it satisfies applicable bioequivalence, labeling, and certification requirements.
- Institutional buyers generally can substitute an approved generic injection unless a clinical, supply, or contracting reason favors Aloxi.
Were there Paragraph IV challenges to Aloxi?
Paragraph IV litigation was commercially relevant during the period when generic manufacturers sought approval before expiry of listed patents. The central legal issue was whether generic palonosetron products infringed valid claims and whether those claims were enforceable.
The practical effect of the historic litigation and ANDA activity was to accelerate the transition from a branded product to a multi-source market. Once the relevant exclusivity barriers expired or were resolved, subsequent generic entrants could rely on the established regulatory pathway rather than reproduce the originator’s clinical development program.
Aloxi does not present the same continuing litigation profile as newer oncology products with active composition-of-matter or formulation patents. Current risk is commercial and contracting-based rather than centered on a live, high-value patent cliff.
What formulations and method-of-use patents protect palonosetron?
The commercial portfolio has included:
Intravenous injection
The IV formulation was the primary value driver. It was suited to chemotherapy administration settings and benefited from once-per-cycle dosing. Its main protections related to palonosetron pharmaceutical compositions and therapeutic use.
Generic injectable palonosetron is the most important source of present price pressure. Hospital purchasing organizations can compare products based on acquisition cost, vial size, supply continuity, and contract terms.
Oral capsule
The oral formulation expanded prescribing flexibility but did not produce a durable commercial moat after generic and alternative antiemetic options became available. Oral use also competes with generic ondansetron, granisetron, and other oral antiemetic regimens.
Combination therapy
Palonosetron is also used in Akynzeo, a fixed-dose combination with netupitant. Akynzeo is a separate branded product and has a distinct patent and regulatory profile. Its commercial protection cannot be assumed to extend to Aloxi because the products have different active ingredients, claims, and regulatory filings.
What is the FDA regulatory status of Aloxi?
Aloxi remains an FDA-approved product for specified CINV indications. Its regulatory status is that of an approved mature drug, not a product with pending initial approval or unresolved safety authorization.
The key regulatory distinction is between:
- The original Aloxi NDA and its approved labeling.
- ANDA-approved generic palonosetron products.
- Separate products containing palonosetron in combination with another active ingredient.
FDA approval does not guarantee equal commercial performance. Generic palonosetron can meet the ANDA standard while competing primarily through price. Brand utilization can persist where physicians or hospitals maintain formulary preference, but that preference is usually weaker after multiple generic approvals.
Which companies commercialize or compete with Aloxi?
The commercial chain has involved Helsinn as the originator and licensor, MGI Pharma as an earlier U.S. commercial partner, and Eisai following its acquisition of MGI Pharma. Regional rights and promotional responsibilities have differed across markets.
Competition comes from four groups:
| Competitor group |
Examples |
Competitive mechanism |
| Generic 5-HT3 antagonists |
Palonosetron, ondansetron, granisetron |
Lower acquisition cost |
| Branded NK1 regimens |
Emend and related products |
Prevention of delayed CINV |
| Fixed-dose combinations |
Akynzeo |
Broad acute and delayed CINV coverage |
| Institutional protocols |
Multi-drug antiemetic regimens |
Protocol standardization and bundled purchasing |
The largest threat to Aloxi is not a single branded rival. It is protocol substitution, in which hospitals use generic palonosetron or another low-cost 5-HT3 antagonist within a broader antiemetic pathway.
How strong is the Aloxi patent estate?
Aloxi’s current patent strength is low from a market-exclusivity standpoint. The estate was commercially important during launch and early lifecycle management, but it no longer provides the level of protection associated with an active composition-of-matter patent.
| Patent-strength factor |
Current assessment |
| Core active-ingredient protection |
Expired or no longer commercially blocking |
| Generic entry barrier |
Low |
| IV formulation protection |
Insufficient to prevent established generic competition |
| Oral formulation protection |
Limited commercial impact |
| Method-of-use protection |
Narrower than product-level exclusivity |
| Manufacturing barriers |
Manageable for established generic manufacturers |
| Litigation exposure |
Primarily historical rather than a current central risk |
Manufacturing is not trivial because injectable products require sterile production, validated processes, quality controls, and reliable supply. Those requirements can limit the number of active suppliers at a given time. They do not, however, restore branded patent exclusivity.
What is Aloxi’s financial trajectory?
Aloxi followed a conventional mature-drug trajectory:
- Early growth came from clinical differentiation, a long half-life, and adoption in chemotherapy protocols.
- Expansion into oral dosing and broader oncology use increased the addressable market.
- Regional licensing and acquisition activity broadened commercialization.
- Generic entry reduced net price and weakened brand bargaining power.
- Current economics depend on residual brand volume, regional availability, contracting, and supply performance.
Public company reporting does not provide a consistent, standalone current revenue series for Aloxi across all territories. Helsinn is privately held, and Eisai reports products within broader financial categories. As a result, precise current Aloxi revenue, EBITDA contribution, and royalty income cannot be derived reliably from standard public filings.
The revenue risk is nevertheless identifiable:
- U.S. IV revenue is exposed to generic substitution and hospital purchasing pressure.
- Oral revenue is exposed to both generic palonosetron and cheaper oral 5-HT3 alternatives.
- International revenue depends on local reimbursement, licensing structures, and generic timing.
- Any remaining brand revenue is likely more stable in protocol-driven accounts than in retail or highly price-sensitive channels.
- Combination products such as Akynzeo may retain more value where their broader antiemetic coverage justifies a premium, but that value should not be attributed to Aloxi standalone.
What generic launch scenarios exist for Aloxi?
The likely market scenarios are:
Base case: continued branded erosion
Generic palonosetron remains available, hospitals maintain multi-source purchasing, and Aloxi retains a smaller share in accounts with established brand protocols. Net pricing remains under pressure.
Upside case: supply-driven brand retention
Manufacturing disruptions, shortages, or limited generic availability can temporarily increase demand for Aloxi. This is a supply event, not a patent-driven recovery.
Downside case: protocol-level replacement
Hospitals replace palonosetron with generic ondansetron, granisetron, or alternative combinations where clinical guidelines and payer economics permit. This creates volume erosion beyond the direct impact of generic palonosetron.
Combination-product defense
Use of netupitant/palonosetron in Akynzeo can preserve palonosetron exposure within a branded combination. That strategy protects a separate product franchise and does not restore Aloxi’s standalone exclusivity.
How does Aloxi compare with Akynzeo and generic ondansetron?
| Factor |
Aloxi |
Akynzeo |
Generic ondansetron |
| Active ingredients |
Palonosetron |
Netupitant plus palonosetron |
Ondansetron |
| Product type |
Single-agent 5-HT3 antagonist |
Fixed-dose NK1/5-HT3 combination |
Single-agent 5-HT3 antagonist |
| Dosing advantage |
Long-acting |
Acute and delayed CINV coverage |
Shorter duration |
| Patent position |
Mature, largely expired |
Separate and potentially stronger estate |
Generic |
| Price position |
Brand premium under pressure |
Premium for combination coverage |
Low cost |
| Main buyer |
Oncology institutions and clinicians |
Protocol-based oncology use |
Hospitals and broad outpatient use |
Aloxi’s clinical duration remains relevant, but its commercial differentiation is weaker than it was before generic palonosetron. Akynzeo has a broader pharmacologic proposition, while ondansetron has scale, familiarity, and low acquisition cost.
What patent litigation and settlement risks affect Aloxi?
The material historical risk involved ANDA applicants, listed patents, and potential early generic launch. Current risk is lower because the principal exclusivity period has passed and generic products are established.
Settlement agreements, if any, must be evaluated from the specific litigation docket and agreement terms. A settlement date alone does not establish the date of generic entry, because launch rights may depend on patent expiry, regulatory approval, manufacturing readiness, and contractual provisions. No current Aloxi settlement should be treated as a primary commercial driver without a corresponding active patent barrier.
Key Takeaways
- Aloxi is a mature palonosetron product with FDA approval for chemotherapy-induced nausea and vomiting.
- Its original U.S. exclusivity began in 2003 and expired years before the current generic market.
- Generic palonosetron is the principal direct threat to Aloxi’s price and volume.
- Generic ondansetron, granisetron, NK1 antagonists, and Akynzeo create broader protocol-level competition.
- The active patent estate is weak as a current barrier to entry.
- Injectable manufacturing requirements can affect supply, but they do not recreate patent exclusivity.
- Standalone Aloxi revenue is not consistently disclosed by Helsinn or Eisai.
- Current commercial value depends on formulary placement, contracting, supply reliability, and residual brand preference.
- Akynzeo provides a separate combination-product franchise and should not be treated as equivalent to Aloxi revenue.
- The most probable long-term trajectory is continued brand erosion with intermittent supply-driven retention.
FAQs About Aloxi Patents, Revenue, and Generic Competition
Is Aloxi still protected by a U.S. composition-of-matter patent?
No. Aloxi’s core commercial exclusivity has expired, and the product is exposed to generic palonosetron competition.
Can a generic manufacturer substitute palonosetron for Aloxi?
An FDA-approved generic palonosetron product can generally be substituted under applicable state substitution rules and institutional formulary policies. Substitution depends on the specific dosage form and purchasing setting.
Does Akynzeo extend the patent life of Aloxi?
No. Akynzeo is a separate fixed-dose combination containing netupitant and palonosetron. Its patent and regulatory rights do not automatically extend Aloxi’s standalone protection.
Is Aloxi revenue publicly reported by Eisai?
Not consistently as a standalone current revenue line. Eisai’s public reporting aggregates products and therapeutic categories, limiting direct calculation of Aloxi sales.
What is the main investment risk for Aloxi?
The principal risk is continued erosion from generic palonosetron and low-cost antiemetic protocols. Supply disruptions can temporarily support brand demand, but they do not represent durable patent-based value.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Aloxi, NDA 021372. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2003). Aloxi (palonosetron hydrochloride) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and generic drug information. https://www.fda.gov/drugs/generic-drugs
-
Eisai Co., Ltd. (n.d.). Annual reports and financial information. https://www.eisai.com/ir/financial/annual.html
-
National Comprehensive Cancer Network. (n.d.). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1421
